Download PDF
Semin Respir Crit Care Med 2020; 41(03): 369-376
DOI: 10.1055/s-0039-3400290
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions

Pencilla Lang
1   Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada
,
Daniel R. Gomez
2   Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
,
David A. Palma
1   Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
25 May 2020 (online)

    Permissions and Reprints

Abstract

The oligometastatic and oligoprogressive disease states have been recently recognized as common clinical scenarios in the management of non-small cell lung cancer (NSCLC). As a result, there has been increasing interest in treating these patients with locally ablative therapies including surgery, conventionally fractionated radiotherapy, stereotactic ablative radiotherapy, and radiofrequency ablation. This article provides an overview of oligometastatic and oligoprogressive disease in the setting of NSCLC and reviews the evidence supporting ablative treatment. Phase II randomized controlled trials and retrospective series suggest that ablative treatment of oligometastases may substantially improve progression-free survival and overall survival, and additional large randomized studies testing this hypothesis in a definitive context are ongoing. However, several challenges remain, including quantifying the possible benefits of ablative therapies for oligoprogressive disease and developing prognostic and predictive models to assist in clinical decision making.

Keywords

NSCLC - SABR - local consolidative therapy - oligometastasis - oligoprogression
 

  • References

  • 1 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (01) 8-10
    CrossrefPubMedSearch in Google Scholar
  • 2 Parikh RB, Cronin AM, Kozono DE. , et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 89 (04) 880-887
    CrossrefPubMedSearch in Google Scholar
  • 3 Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 2009; 48 (04) 578-583
    CrossrefPubMedSearch in Google Scholar
  • 4 Torok JA, Gu L, Tandberg DJ. , et al. Patterns of distant metastases after surgical management of non-small-cell lung cancer. Clin Lung Cancer 2017; 18 (01) e57-e70
    CrossrefPubMedSearch in Google Scholar
  • 5 Yano T, Okamoto T, Haro A. , et al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer 2013; 82 (03) 431-435
    CrossrefPubMedSearch in Google Scholar
  • 6 Palma DA, Olson R, Harrow S. , et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393 (10185): 2051-2058
    CrossrefPubMedSearch in Google Scholar
  • 7 Gomez DR, Tang C, Zhang J. , et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase ii, randomized study. J Clin Oncol 2019; 37 (18) 1558-1565
    CrossrefPubMedSearch in Google Scholar
  • 8 Iyengar P, Wardak Z, Gerber DE. , et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018; 4 (01) e173501
    CrossrefPubMedSearch in Google Scholar
  • 9 Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1–3 Metastases) Cancer (SABR-COMET-3). Available at: https://clinicaltrials.gov/ct2/show/NCT03862911 . Accessed June 23, 2019
    PubMed
  • 10 Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4–10 Oligometastatic Tumors (SABR-COMET-10). Available at: https://clinicaltrials.gov/ct2/show/NCT03721341 . Accessed June 23, 2019
    PubMed
  • 11 Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE). Available at: https://clinicaltrials.gov/ct2/show/NCT02759783 . Accessed June 23, 2019
    PubMed
  • 12 Systemic Therapy with or without Local Consolidative Therapy in Treating Patients with Oligometastatic Solid Tumor. Available at: https://clinicaltrials.gov/ct2/show/NCT03599765 . Accessed June 23, 2019
    PubMed
  • 13 Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients with Oligoprogressive Metastatic Cancers of the Breast and Lung. Available at: https://clinicaltrials.gov/ct2/show/NCT03808662 . Accessed June 23, 2019
    PubMed
  • 14 Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON). Available at: https://clinicaltrials.gov/ct2/show/record/NCT02417662 . Accessed June 23, 2019
    PubMed
  • 15 Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC). Available at: https://clinicaltrials.gov/ct2/show/NCT02756793 . Accessed June 23, 2019
    PubMed
  • 16 OMEGA, Local Ablative Therapy in Oligometastatic NSCLC (OMEGA). Available at: https://clinicaltrials.gov/ct2/show/NCT03965468 . Accessed June 23, 2019
    PubMed
  • 17 Gomez DR, Blumenschein Jr GR, Lee JJ. , et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17 (12) 1672-1682
    CrossrefPubMedSearch in Google Scholar
  • 18 Palma DA, Salama JK, Lo SS. , et al. The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 2014; 11 (09) 549-557
    CrossrefPubMedSearch in Google Scholar
  • 19 Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40 (02) 107-111
    CrossrefPubMedSearch in Google Scholar
  • 20 Twomey P, Montgomery C, Clark O. Successful treatment of adrenal metastases from large-cell carcinoma of the lung. JAMA 1982; 248 (05) 581-583
    CrossrefPubMedSearch in Google Scholar
  • 21 Ambrogi V, Tonini G, Mineo TC. Prolonged survival after extracranial metastasectomy from synchronous resectable lung cancer. Ann Surg Oncol 2001; 8 (08) 663-666
    CrossrefPubMedSearch in Google Scholar
  • 22 Khan AJ, Mehta PS, Zusag TW. , et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 2006; 81 (02) 163-167
    CrossrefPubMedSearch in Google Scholar
  • 23 Wroński M, Arbit E, Burt M, Galicich JH. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995; 83 (04) 605-616
    CrossrefPubMedSearch in Google Scholar
  • 24 Ashworth AB, Senan S, Palma DA. , et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014; 15 (05) 346-355
    CrossrefPubMedSearch in Google Scholar
  • 25 Lewis SL, Porceddu S, Nakamura N. , et al. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol 2017; 40 (04) 418-422
    CrossrefPubMedSearch in Google Scholar
  • 26 Solomon BJ, Mok T, Kim D-W. , et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23) 2167-2177
    CrossrefPubMedSearch in Google Scholar
  • 27 Rosell R, Carcereny E, Gervais R. , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (03) 239-246
    CrossrefPubMedSearch in Google Scholar
  • 28 Huang CY, Chen BH, Chou WC, Yang CT, Chang JW. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis 2018; 10 (04) 2070-2078
    CrossrefPubMedSearch in Google Scholar
  • 29 Reck M, Rodríguez-Abreu D, Robinson AG. , et al; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375 (19) 1823-1833
    CrossrefPubMedSearch in Google Scholar
  • 30 Yoshida T, Yoh K, Niho S. , et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer 2015; 90 (03) 477-483
    CrossrefPubMedSearch in Google Scholar
  • 31 Weickhardt AJ, Scheier B, Burke JM. , et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7 (12) 1807-1814
    CrossrefPubMedSearch in Google Scholar
  • 32 Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol 2016; 89 (1066): 20160251
    CrossrefPubMedSearch in Google Scholar
  • 33 Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer 2010; 69 (03) 251-258
    CrossrefPubMedSearch in Google Scholar
  • 34 Botsa EI, Thanou IL, Papatheodoropoulou AT, Thanos LI. Thermal ablation in the management of adrenal metastasis originating from non-small cell lung cancer: a 5-year single-center experience. Chin Med J (Engl) 2017; 130 (17) 2027-2032
    CrossrefPubMedSearch in Google Scholar
  • 35 Patchell RA, Tibbs PA, Walsh JW. , et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322 (08) 494-500
    CrossrefPubMedSearch in Google Scholar
  • 36 Tanvetyanon T, Robinson LA, Schell MJ. , et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26 (07) 1142-1147
    CrossrefPubMedSearch in Google Scholar
  • 37 Bonnette P, Puyo P, Gabriel C. , et al; Groupe Thorax. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001; 119 (05) 1469-1475
    CrossrefPubMedSearch in Google Scholar
  • 38 Chmura SJ, Winter K, Salama JK. , et al. Phase I trial of stereotactic body radiation therapy (SBRT) to multiple metastatic sites: a NRG oncology study. International Journal of Radiation Oncology Biology Physics 2018; 102 (03) S68-S69
    PubMedSearch in Google Scholar
  • 39 Hasselle MD, Haraf DJ, Rusthoven KE. , et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 2012; 7 (02) 376-381
    CrossrefPubMedSearch in Google Scholar
  • 40 Merino Lara T, Helou J, Poon I. , et al. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?. Lung Cancer 2018; 124: 219-226
    CrossrefPubMedSearch in Google Scholar
  • 41 Holy R, Piroth M, Pinkawa M, Eble M. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011; 187 (04) 245-251
    CrossrefPubMedSearch in Google Scholar
  • 42 Künzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: actual limitations and potential solutions in the future. World J Hepatol 2011; 3 (01) 8-14
    CrossrefPubMedSearch in Google Scholar
  • 43 Vogl TJ, Naguib NN, Lehnert T, Nour-Eldin NE. Radiofrequency, microwave and laser ablation of pulmonary neoplasms: clinical studies and technical considerations--review article. Eur J Radiol 2011; 77 (02) 346-357
    CrossrefPubMedSearch in Google Scholar
  • 44 de Baère T, Aupérin A, Deschamps F. , et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26 (05) 987-991
    CrossrefPubMedSearch in Google Scholar
  • 45 Callstrom MR, Charboneau JW, Goetz MP. , et al. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol 2006; 35 (01) 1-15
    CrossrefPubMedSearch in Google Scholar
  • 46 Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro-oncol 2015; 17 (01) 122-128
    PubMedSearch in Google Scholar
  • 47 Andrews DW, Scott CB, Sperduto PW. , et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363 (9422): 1665-1672
    CrossrefPubMedSearch in Google Scholar
  • 48 Churilla TM, Weiss SE. Emerging trends in the management of brain metastases from non-small cell lung cancer. Curr Oncol Rep 2018; 20 (07) 54
    CrossrefPubMedSearch in Google Scholar
  • 49 Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010; 5 (07) 932-934
    CrossrefPubMedSearch in Google Scholar
  • 50 Herbst RS, Baas P, Kim D-W. , et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027): 1540-1550
    CrossrefPubMedSearch in Google Scholar
  • 51 Conibear J, Chia B, Ngai Y. , et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open 2018; 8 (04) e020690
    CrossrefPubMedSearch in Google Scholar
  • 52 McDonald F, Hanna GG. Oligoprogressive oncogene-addicted lung tumours: does stereotactic body radiotherapy have a role? Introducing the HALT trial. Clin Oncol (R Coll Radiol) 2018; 30 (01) 1-4
    CrossrefPubMedSearch in Google Scholar
  • 53 Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations. Available at: https://clinicaltrials.gov/ct2/show/NCT03410043 . Accessed June 23, 2019
    PubMed
  • 54 Phase III Trial of (LCT) After Nivolumab and Ipilimumab. Available at: https://clinicaltrials.gov/ct2/show/NCT03391869 . Accessed June 23, 2019
    PubMed
  • 55 Li S, Zhu R, Li D, Li N, Zhu X. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis 2018; 10 (06) 3701-3713
    CrossrefPubMedSearch in Google Scholar
  • 56 Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA. An update on predictive biomarkers for treatment selection in non-small cell lung cancer. J Clin Med 2018; 7 (06) E153
    CrossrefPubMedSearch in Google Scholar
  • 57 Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am 2017; 31 (01) 13-29
    CrossrefPubMedSearch in Google Scholar
  • 58 Hanssen A, Riebensahm C, Mohme M. , et al. Frequency of circulating tumor cells (CTC) in patients with brain metastases: implications as a risk assessment marker in oligo-metastatic disease. Cancers (Basel) 2018; 10 (12) E527
    CrossrefPubMedSearch in Google Scholar
  • 59 Lindsay DP, Moon DH, Mahbooba Z. , et al. Quantification of circulating tumor cells as a biomarker for surveillance in oligometastatic patients after definitive radiation therapy. Journal of Clinical Oncology 2018; 36 (15_Suppl): e24106-e24106
    CrossrefPubMedSearch in Google Scholar
  • 60 Cabanero M, Tsao MS. Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Curr Oncol 2018; 25 (Suppl. 01) S38-S44
    CrossrefPubMedSearch in Google Scholar
  • 61 Wong AC, Watson SP, Pitroda SP. , et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 2016; 122 (14) 2242-2250
    CrossrefPubMedSearch in Google Scholar
  • 62 Jensen GL, Yost CM, Mackin DS. , et al. Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer. Radiother Oncol 2018; 126 (02) 362-367
    CrossrefPubMedSearch in Google Scholar
  • 63 Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS). Available at: https://clinicaltrials.gov/ct2/show/NCT03965468 . Accessed June 23, 2019
    PubMed
  • 64 Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res 2018; 24 (23) 5792-5806
    CrossrefPubMedSearch in Google Scholar
  • 65 Maintenance Chemotherapy with or without Local Consolidative Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03137771 . Accessed June 23, 2019
    PubMed